PEN
Penumbra Inc
NYSE · Healthcare · Medical - Devices · US
$324.05
+0.51%Oct 20, 2026, 13:00 UTC
The U.S. Food and Drug Administration granted Penumbra clearance for its Lightning computer-assisted vacuum thrombectomy technology to treat deep vein thrombosis.
Source:Oct 6, 2026, 13:00 UTC
Penumbra, Inc. announced results from a subset analysis of the STORM-PE randomized controlled trial showing a correlation between wearable-captured daily step activity and the clinical 6-minute walk test in patients with pulmonary embolism.
Source:Jul 30, 2026, 20:05 UTC
Penumbra, Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 29, 2026, 09:49 UTC
Magnendo Corp. closed an $18 million Series A financing round led by Penumbra, Inc. with participation from institutional investors.
Source:Jul 22, 2026, 18:35 UTC
Penumbra announced results of the THUNDER study demonstrating that its THUNDERBOLT CAVT system is safe and effective for stroke care.
Source:Jun 18, 2026, 17:51 UTC
Penumbra receives CE Mark approval in Europe for its THUNDERBOLT product, expanding access to stroke treatment.
Source:Jun 15, 2026, 13:00 UTC
Penumbra secured CE Mark in Europe for its THUNDERBOLT computer assisted vacuum thrombectomy technology for acute ischemic stroke.
Source:Jun 11, 2026, 20:05 UTC
Penumbra, Inc. received FDA clearance for its THUNDERBOLT computer assisted vacuum thrombectomy technology for acute ischemic stroke.
Source: